Zacks Investment Research upgraded shares of Affimed (NASDAQ:AFMD) from a hold rating to a buy rating in a research note released on Wednesday morning. Zacks Investment Research currently has $2.25 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany. “
NASDAQ:AFMD opened at $2.10 on Wednesday. The company has a quick ratio of 5.58, a current ratio of 5.61 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $131.02, a price-to-earnings ratio of -2.69 and a beta of 2.30. Affimed has a 12 month low of $1.15 and a 12 month high of $2.85.
Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC lifted its stake in shares of Affimed by 483.0% in the fourth quarter. Virtu Financial LLC now owns 85,562 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 70,886 shares in the last quarter. Two Sigma Securities LLC bought a new position in shares of Affimed in the fourth quarter valued at $136,000. Dimensional Fund Advisors LP lifted its stake in shares of Affimed by 817.9% in the third quarter. Dimensional Fund Advisors LP now owns 137,783 shares of the biopharmaceutical company’s stock valued at $310,000 after buying an additional 122,773 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in shares of Affimed in the third quarter valued at $658,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3338264/affimed-afmd-lifted-to-buy-at-zacks-investment-research.html.
Affimed Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.